Tarsus Pharmaceuticals, Inc.
TARS
$59.83
$0.180.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 162.05M | 151.67M | 118.70M | 102.66M | 78.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 162.05M | 151.67M | 118.70M | 102.66M | 78.34M |
| Cost of Revenue | 31.75M | 28.96M | 24.59M | 21.83M | 19.62M |
| Gross Profit | 130.31M | 122.71M | 94.10M | 80.83M | 58.72M |
| SG&A Expenses | 136.43M | 130.68M | 108.63M | 103.01M | 85.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 168.18M | 159.64M | 133.23M | 124.84M | 104.62M |
| Operating Income | -6.12M | -7.98M | -14.53M | -22.18M | -26.28M |
| Income Before Tax | -4.62M | -6.31M | -12.59M | -20.34M | -25.12M |
| Income Tax Expenses | 2.35M | 2.06M | -- | -- | -- |
| Earnings from Continuing Operations | -6.97M | -8.37M | -12.59M | -20.34M | -25.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.97M | -8.37M | -12.59M | -20.34M | -25.12M |
| EBIT | -6.12M | -7.98M | -14.53M | -22.18M | -26.28M |
| EBITDA | -5.69M | -7.53M | -14.07M | -21.73M | -25.82M |
| EPS Basic | -0.16 | -0.20 | -0.30 | -0.48 | -0.64 |
| Normalized Basic EPS | -0.08 | -0.03 | -0.18 | -0.30 | -0.42 |
| EPS Diluted | -0.16 | -0.20 | -0.30 | -0.48 | -0.64 |
| Normalized Diluted EPS | -0.08 | -0.03 | -0.18 | -0.30 | -0.42 |
| Average Basic Shares Outstanding | 42.96M | 42.78M | 42.61M | 42.36M | 39.35M |
| Average Diluted Shares Outstanding | 42.96M | 42.78M | 42.61M | 42.36M | 39.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |